NCT06879041 - A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

April 16, 2029

Study Completion Date

April 16, 2029

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG

AZD2287

AZD2287 is administered through intravenous injection.

DRUG

AZD2275

AZD2275 is administered through intravenous infusion.

DRUG

AZD2284

AZD2284 is administered through intravenous injection.

Trial Locations (11)

181

NOT_YET_RECRUITING

Research Site, Pretoria

3002

RECRUITING

Research Site, East Melbourne

4013

NOT_YET_RECRUITING

Research Site, Durban

7925

NOT_YET_RECRUITING

Research Site, CapeTown

10032

NOT_YET_RECRUITING

Research Site, New York

33165

RECRUITING

Research Site, Miami

44195

NOT_YET_RECRUITING

Research Site, Cleveland

60637

NOT_YET_RECRUITING

Research Site, Chicago

68130

RECRUITING

Research Site, Omaha

97239

NOT_YET_RECRUITING

Research Site, Portland

02215

RECRUITING

Research Site, Boston